UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: CBLI |
| Industry | Pharmaceuticals |
| Founded | Cleveland, Ohio, 2003 |
| Headquarters | Buffalo, New York, USA |
|
Key people
|
Yakov Kogan, CEO Andrei Gudkov, Chief Scientific Officer |
| Products | Anti-radiation and oncological products |
| Subsidiaries | Incuron, LLC Panacela Labs, Inc. |
| Website | www |
Yakov Kogan, CEO
Andrei Gudkov, Chief Scientific Officer
Cleveland BioLabs, Inc. (Nasdaq: CBLI) is a clinical-stage biotechnology company with a focus on oncology development. It specializes in research and development of products with the potential to treat cancer and protect against death following acute radiation syndrome. The company was founded in 2003 and is headquartered in Buffalo, New York. It has license agreements and collaborations with the Cleveland Clinic, Roswell Park Cancer Institute, the Children’s Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute.
Cleveland BioLabs was founded in partnership with the Cleveland Clinic in 2003 and moved to the Buffalo Niagara Medical Campus in 2007.
The following table shows key financial figures for the company for 2011, 2012 and 2013 (parenthesis represent negative figures).
Cleveland Biolabs has two majority-owned subsidiaries:
| 2014-01-24 | Downgrade | Oppenheimer | Outperform to Market Perform | $0.75 to $1.13 |
| 2014-01-24 | Downgrade | Cantor Fitzgerald | Buy to Hold | $4.00 to $2.00 |
| 2013-03-21 | Initiated | Cantor Fitzgerald | Buy | $4 |
| 2012-12-06 | Initiated | Oppenheimer | Outperform | $3 |
| 2012-12-04 | Initiated | Burrill Institutional Research | Mkt Outperform | $4 |
| 2011-02-02 | Initiated | Wedbush | Outperform | $10 |
| 2010-10-13 | Downgrade | WBB Securities | Strong Buy to Hold | $6.50 to $6.50 |
| 2010-09-17 | Reiterated | Rodman & Renshaw | Mkt Outperform | $8 to $11 |
| 2010-07-21 | Downgrade | WBB Securities | Strong Buy to Speculative Buy | $6.50 |
| 2009-09-29 | Initiated | Rodman & Renshaw | Mkt Outperform | $8 |
| 2014-01-24 | Downgrade | Oppenheimer | Outperform to Market Perform | $0.75 to $1.13 |
| 2014-01-24 | Downgrade | Cantor Fitzgerald | Buy to Hold | $4.00 to $2.00 |
| 2013-03-21 | Initiated | Cantor Fitzgerald | Buy | $4 |
| 2012-12-06 | Initiated | Oppenheimer | Outperform | $3 |
| 2012-12-04 | Initiated | Burrill Institutional Research | Mkt Outperform | $4 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CBLI 5 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| KCG Holdings, Inc. | 52091 |
| Saiers Capital, LLC | 10154 |
| BLACKROCK ADVISORS LLC | 2800 |
| BlackRock Fund Advisors | 741 |
| LADENBURG THALMANN FINANCIAL SERVICES INC | 265 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Gudkov Andrei V Chief Scientific Officer | 2.66% (1517370) | CBLI / |
| Fonstein Michael CEO, President | 2.06% (1176465) | CBLI / |
| BROWN JULIA R | 0.20% (116482) | BIOD / CBLI / TRGT / |
| Principi Anthony | 0.09% (52419) | CBLI / EGL / IMMY / |
| Hohn David C | 0.08% (43049) | CBLI / |
| DiCorleto Paul E | 0.07% (41968) | CBLI / |
| KASTEN BERNARD L | 0.05% (26998) | CBLI / ENZ / |
| Lyons C Neil Chief Financial Officer | 0.04% (20273) | CBLI / |
| Kogan Yakov COO, Secretary | 0.03% (17377) | CBLI / |
| Perez Hector Daniel | 0.02% (12749) | CBLI / |
| Antal James | 0.01% (8000) | CBLI / SIGA / |
| SALUCK RANDY S. | 0.01% (6116) | CBLI / |
UM